



*Transforming Today's Science
Into Tomorrow's Cures*



VOLUME IV

ISSUE 5

www.SamaritanPharma.com

October, 2007

Samaritan Adds 11th Revenue-Generating Product to Sales Pipeline: ROPYDAN®

Samaritan Pharmaceuticals, Inc. signed an exclusive distribution agreement with EUSA Pharma, Ltd., Oxford, England, to launch, promote, sell and support the topical anesthetic patch Ropydan® in Greece and Cyprus.



Ropydan® provides a Controlled Heat-Assisted Drug Delivery (CHADD) technology allowing for a targeted, rapid absorption and deep anesthetic effect of the drugs lidocaine and tetracaine. The topically administered patch plus the heating element to warm the surface temperature of the skin instigates a vasodilatory effect. Consequently, two major benefits are observed: the rapid onset of anesthesia and the increased accessibility to blood vessels.

Because of Ropydan's® noninvasive delivery system and rapid impact, it is an especially effective pain management drug with children. Also, patients who present difficult venous access for cannulation are good candidates for Ropydan®.



Sample of the Ropydan® topical anesthetic patch.

On Aug. 3, 2007 Samaritan signed an exclusive agreement with EUSA Pharma

See "Drugs" Page 4

Samaritan to Host 2007 Annual Meeting October 23, 2007


Samaritan Pharmaceuticals, Inc. will host its annual shareholders meeting on Tuesday, Oct. 23 at 10:00 EDT in the VIP Conference Room of Samaritan Therapeutics, 1000 de la Gauchetie West, Montreal, Canada.

Immediately following the meeting attendees will be given a guided tour of the new Samaritan/McGill collaborative research laboratory inside the McGill University Research Institute, McGill University.

The laboratory tour is in a restricted access building with government issued, photo I.D. required to gain entry. Therefore, all shareholders planning on participating in the tour need to register in advance, as soon as possible. This will allow Samaritan headquarters time to facilitate the proper credentials.

Due to limited space, there is no guarantee that everyone will be able to attend the tour. To register, please contact Richard Brown, Investor Relations, (702) 735-7001.

FYI: Proxy materials for Samaritan's 2007 Annual Meeting of Shareholders maybe found on the SP Web site under the new Security and Exchange Commission, "Notice and Access" rule, at <http://www.livproxy.com>.



Samaritan Staff

Dr. Janet Greeson
C.E.O. and President

Eugene Boyle
C.F.O. and C.O.O.

Dr. Tom Lang
Chief Drug Development Officer

George Weaver
Regulatory Affairs

Kristi Eads
V.P. of Business Development

Dr. Christos Dakas
Managing Director, S.E.

Dianne Thompson
Comptroller

Richard Brown
Investor Relations

Barrie Fuller
Operations and
Investor Relations

Terri Hess
Office Manager

Monica Jones
Administrative Assistant

Rosemary Fuller
Executive Assistant

Marcie Still
Secretary

Mike Smith
Information Technology

Thomas Vosicky
Creative and Web Design

STROKE

When the Brain Attacks

Stroke Identification

During a BBQ, a friend stumbled and took a little fall—she assured everyone that she was fine (they offered to call paramedics) and had just tripped over a brick because of her new shoes. They got her cleaned up and got her a new plate of food—while she appeared a bit shaken up, Ingrid went about enjoying herself the rest of the evening. Ingrid’s husband called later telling everyone that his wife had been taken to the hospital—(at 6:00pm Ingrid passed away.) She had suffered a stroke at the BBQ. Had they known how to identify the signs of a stroke, perhaps Ingrid would be with us today. Some don’t die. They end up in a helpless, hopeless condition instead.

It only takes a minute to read this...

A neurologist says that if he can get to a stroke victim within 3 hours he can totally reverse the effects of a stroke...totally. He said the trick was getting a stroke recognized, diagnosed, and then getting the patient medically cared for within 3 hours, which is tough.

“STR” ... How to Recognize a Stroke

Neurologists say if they can get to a stroke victim within three hours, they can totally reverse its effects. The trick is recognizing the condition, diagnosing it and then getting the patient proper medical care within the three hours, which can be difficult.

Sometimes the symptoms of a stroke are hard to identify and the lack of awareness can spell disaster. Time works against a stroke victim and the patient could suffer severe brain damage if people nearby fail to recognize the stroke symptoms.

By asking the following simple questions, however, the life of a stroke victim might be saved. **Remember...S-T-R**

S: Ask the individual to smile

Sudden numbness or weakness of the face, arms or legs is a common symptom of stroke. A person experiencing a stroke would not be able to smile.

T: Ask the individual to talk

Sudden confusion, trouble speaking or understanding is another common symptom of stroke. Either the patient would not be able to speak or replies in a kind of gibberish.

R: Ask the individual to raise BOTH arms

Sudden trouble walking, dizziness or loss of balance or coordination is another common symptom of stroke.

Right Brain Injury

Paralyzed
Left Side

Special
Perceptual
Deficits

Quick
Impulsive
Behavioral
Style

Memory
Deficits


Left Brain Injury

Paralyzed
Right Side

Speech-
Language
Deficits

Slow
Cautious
Behavioral
Style

Memory
Deficits



Additional ways of determining if a person is having a stroke are:

- Ask the person to stick out their tongue. If the tongue is crooked or goes to one side or the other, consider it an indication.
- Sudden trouble seeing out of both eyes.
- Sudden severe headache with no known cause. If a person near you experiences any or one of these symptoms, *take them seriously* and call 911 immediately.

Stroke Facts:

There are three basic classifications of stroke:

Ischemic Stroke--The most common type occurring when a blood clot or other material blocks an artery supplying blood to the brain.

Hemorrhage Stroke: This type of stroke occurs when an artery in the brain bursts, causing blood to flow into surrounding tissue.

Transient Ischemic Attack (TIA): An attack lasting a few minutes, sometimes called a “mini-stroke.” TIA’s do not cause long-term damage but do put the patient in an elevated risk for an acute attack.

- Stroke accounted for about one out of every 15 deaths in the United States in 2003. When considered separately from other cardiovascular diseases, stroke ranks No. 3 among all causes of death, behind heart disease and cancer.
- On average, about every 3 minutes someone dies of a stroke.
- More women than men die of stroke each year. In 2003, women accounted for 61percent of all stroke deaths in the U.S.
- Physical activity, a healthy diet and being a non-smoker reduce the risk of stroke.

Above statistics from: American Heart Association

Please Welcome Samaritan's Newest Member - World Renowned Physician and HIV Researcher - Dr. James Hildreth

It's official! As of October 3, 2007, James E.K. Hildreth, M.D., a world renowned physician and HIV researcher, joins our Scientific Advisory Board.

The work of Dr. Hildreth in HIV/AIDS dates back to 1986 and focuses on blocking HIV infection by learning how HIV gets into cells. He has published more than 80 scientific articles and holds six patents. Originally from Arkansas, Dr. Hildreth holds degrees from Harvard University, Oxford University and Johns Hopkins University where he was the first African American to earn full professorship with tenure in the basic sciences.

Currently, Dr. Hildreth serves as the Director for the Center for AIDS Health Disparities Research and Professor of Medicine at Meharry Medical College in Nashville, Tennessee. Dr. Hildreth is also an Adjunct Professor of Pharmacology and Molecular Sciences, at Johns Hopkins School of Medicine, Baltimore, Maryland.

In addition, Dr. Hildreth is a past member of the National Institutes of Health/the National Institute of Allergy and Infectious Diseases (AIDS Research Review Study Section). His research has been focused on the relationship between adhesion molecules, lipid rafts, and the biology of human retroviruses (HIV).

Samaritan's lead Phase II HIV drug, SP-01A's mechanism of action is thought to be related to cholesterol modulation and Dr. Hildreth's research studying cholesterol sequestration as a preventive measure for HIV Infection is of special interest. Related HIV cholesterol publications include, "Lipid rafts and HIV pathogenesis: virion-associated cholesterol is required for fusion and infection of susceptible cells, AIDS Res Hum Retroviruses. 2003 Aug;19(8):675-87" and "Cholesterol depletion of human immunodeficiency virus type 1 and simian immunodeficiency virus with beta-cyclodextrin inactivates and permeabilizes the virions: evidence for virion-associated lipid rafts. J Virol. 2003 Aug;77(15):8237-48."

Dr. Janet Greeson CEO of Samaritan stated, "We are looking forward to Dr. Hildreth's participation with Samaritan's drug development team and our scientific advisory board. He is futuristic and considered a significant thought leader in the world



Bio Partnering Europe

This year's BioPartnering Conference was held on October 8-9, 2007 in London, England. The conference was very successful. There were more than 650 companies and over 1300 international attendees. The center was packed with members of the international life science community networking and participating in over 4300 one-to-one meetings. This conference included 130 presenting companies, sessions and workshops from industry leaders, and the best life science partnering opportunities in Europe.

Samaritan Pharmaceuticals highlighted its most innovative HIV, Hepatitis C and Alzheimer's Drugs. Dr. Janet Greeson discussed the drugs in Samaritan's clinical trial pipeline that offer a substantial benefit over what is already on the market, with the objective of finding a Pharma partner or licensing deal.



Samaritan CEO Speaker at BIOTECH IN EUROPE INVESTOR FORUM in Switzerland



Dr. Janet Greeson, CEO of Samaritan Pharmaceuticals, Inc., was an invited speaker on a pharmaceutical partnership panel at the 7th Annual Biotech in Europe Investor Form, held Oct. 2-3, 2007 in Zurich, Switzerland.

The annual Swiss-based international biotech forum hosts institutional investors, bankers and analysts together with small cap companies, leading public and late stage companies.

More than 350 delegates representing approximately 20 countries attended the two-day event sponsored by Sachs Associates and held in the Swissôtel Zürich, Zurich, Switzerland.

Greeson served on a six-member panel which addressed the issue of pharma partnering from the perspective of the small and larger company viewpoint.

Quote from Dr. Greeson, "All biotech companies want to be acquired, but it is a challenge to attract attention

"If you're talking about raising shareholder value, then a major pharma buy is the way," Greeson said.

The pharma partnering panel was chaired by Dimitri Dimitriou, CEO of DyoDelta Biosciences, London, who also spoke about small company pharma partnering.

Other members of the panel, all representing major pharma, included: Dr. Andrew Wood, Research Acquisitions, Europe, Lilly; Dr. Margaret Beer, Licensing and External Research, Europe, Merck & Co., Inc.; Dr. Markus Ewert, Global Head of Search and Evaluation for Cardiovascular and Metabolism, Novartis; and Dr. Alex Chanas, Director, Licensing and Development, Pfizer Inc.

Attendees at BIOTECH had the opportunity to attend a variety of panel discussions similar to the one featuring Dr. Greeson. In addition, the agenda offered large group lectures and private meeting rooms to facilitate individual networking between two companies.

Global Life Science Ventures (GLSV) a venture capital fund, conducted a survey to evaluate the financial health of biotech investing, releasing the results during the forum.

Among the 200 respondents, biotech executives and members of the investment community represented 40 and 50 percent of the participants, respectively. Overall, their outlook for the sector remained clearly optimistic.

There was a positive shift in the perception of the funding environment for early-stage biotech companies in Europe, while the U.S. funding is considered good or excellent.

Europe and U.S. markets are now considered to have even market conditions for IPOs. And, the two strongest factors for a successful IPO continues to be offering a late stage product and a strong management team.

"Drugs" Continued

which is FDA approved under the brand name SYN-ERA®, owned by ZARS Pharmaceuticals, Inc., and marketed by Endo Pharmaceuticals, Inc. in the U.S.

Currently, Samaritan Pharmaceuticals is utilizing the FDA approved regulatory file from the U.S. in preparing marketing applications for Rapydan® with regulatory authorities in Greece and Cyprus to gain country marketing authorization drug approval in those countries.

In less than a year, with the exception of Amphocil®, Samaritan's management team has now in-licensed a total of 11 revenue generating products. The exclusive distribution agreements associated with these drugs are targeted for sales through Samaritan Pharmaceuticals Europe located in Athens, Greece.

- Amphocil®-fungal infection therapy
- Replagal®-treats Fabry Disease
- Elaprase®-treats Hunter Syndrome
- Infasurf®-for respiratory distress Syndrome
- Oramorph®-narcotic pain medication
- Morphine Sulphate®-narcotic pain medication
- Methadone HCL®- drug addiction therapy.
- Naltrexone HCL®-opiod antagonist
- Naloxone®-opiod antagonist
- Mepivamol®-general anesthesia
- Rapydan®-topical anesthetic patch



Samaritan's Family of drugs including the most recent drug Rapydan®